wow $AKRO the robots gapped and trapped people up to $58.20 now almost half that $30.50 wonder if this bounces or even holds $30? any opinions are welcomed Message in reply to: Based on today's dataset, AKRO is seeking to resuscitate the failed phase-2 trial in cirrhotic NASH: https://www.fiercebiotech.com/biotech/akero-bruised-earlier-failure-soars-liver-scarring-improves-longer-mash-trial